Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer

Survival Outcomes of Residual Disease in Patients With Triple-Negative Breast Cancer Following Neoadjuvant Therapy: A Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07714382

Acronym

ReS-TNBC

Enrollment

100

Registered

2026-07-20

Start date

2026-05-01

Completion date

2026-07-01

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple-Negative Breast Cancer (TNBC)

Keywords

Triple-Negative Breast Cancer (TNBC)

Brief summary

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival

Interventions

PROCEDUREChemo-radiotherapy alone

Chemo and radiotherapy before surgery

OTHERNot applicable- observational study

Not applicable. This is a retrospective observational cohort study. No study intervention is administered. Data will be collected retrospectively from patients' medical records, and all treatments were provided as part of routine clinical care.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR). Complete clinical, pathological, treatment, and follow-up data available in the medical records.

Exclusion criteria

* Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery. Patients with incomplete or missing essential clinical, pathological, or follow-up data. Patients with a history of another primary malignancy that could affect survival analysis.

Design outcomes

Primary

Measure	Time frame
Disease free survival	Up to 3 years

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026